Abstract Black/African American populations, globally, bear the greatest prostate cancer (CaP) burden compared to other racial/ethnic groups. Addressing CaP disparities in Black men is complex, requiring a patient-centered, community-centric and comprehensive approach. This study integrates iCCaRE Consortium findings and broader literature to address unmet needs in survivorship care. The iCCaRE Consortium implemented five complementary pilot studies using mixed-methods designs, including feasibility trials, qualitative research, and observational analyses across the United States and sub-Saharan Africa. Descriptive statistics, subgroup analyses, and qualitative thematic analyses were performed across these studies. Collectively, projects addressed multilevel determinants including social, behavioral, and biological drivers of disparities. Project 1 implemented a Virtual Reality Assistant (ViRA) across clinical and community settings, with ongoing evaluation in pragmatic trials. Project 2 showed strong patient preference for home-based cancer care. Project 3 enrolled demonstrated trends toward improved health-related quality of life. Project 4 identified key themes influencing survivorship experiences. Project 5 identified biological mechanisms linking stress, immune modulation, and symptom burden. The iCCaRE pilot projects demonstrate the feasibility and early impact of a consortium-based, transdisciplinary approach to addressing CaP disparities in Black men. These findings highlight the importance of integrating patient-centered interventions, community engagement, and biological insights to inform scalable strategies aimed at improving survivorship outcomes and advancing health equity. The iCCaRE Consortium demonstrates that a transatlantic, patient-centered, and multidisciplinary approach integrating social, clinical, and biological factors can generate scalable strategies to improve survivorship outcomes and advance equity in CaP care for Black men.
Patient experience and quality of life in a decentralized cancer care model for advanced prostate cancer.
e13611 Background: Decentralized cancer care models may reduce treatment burden for patients with advanced prostate cancer (CaP), particularly those facing mobility, transportation, of scheduling challenges. However, prospective patient-reported experience and quality-of-life data comparing home- versus clinic-based oncology care remain limited. Mayo Clinic Cancer CARE Beyond Walls (CCBW) is a patient-centered program designed to deliver selected standard-of-care cancer therapies in the home with virtual clinical oversight. This observational study evaluated patient-reported experience, feasibility, safety, and quality of life among men with advanced or metastatic CaP receiving care at home. Methods: Men with advanced/metastatic CaP receiving active standard-of-care therapy including hormone-based treatments, oral anticancer therapies, anti-bone resorptive agents, or intravenous chemotherapy who were participating in a CCBW randomized trial were enrolled into a companion observational study. After confirmation of treatment tolerance in clinic, patients received home-based care for 24 weeks (Arm A) or in-clinic care for 8 weeks followed by home-based care for 16 weeks (Arm B). Patient-reported outcomes were collected at baseline and Weeks 8, 16, and 24, using CAHPS-based measures and CCBW-specific surveys assessing overall cancer care experience, patient preference for site of care, comfort with home infusions, functional/symptom assessment and quality of life. Descriptive analyses were performed. Results: Eighteen participants were analyzed (Arm A n = 10; Arm B n = 8). Participants were medically stable, and predominantly insured by Medicare. Survey completion was 100% at baseline and 83% at all follow-up time points. At Weeks 16 and 24 when all respondents had received home-based care, 100% and 92% reported being “quite a bit” or “very much” comfortable receiving treatment at home. Communication with at-home and remote nursing teams was rated highly, and most respondents reported transition, scheduling, and equipment use easy or very easy. At Weeks 16 and 24, 45% and 40% of respondents reported improved quality of life from receiving home-based care, with no reports of worsening. No emergency department visits, hospitalizations, or urgent care visits occurred in either arm. Conclusions: In this prospective, observational study, home-based oncology care delivered through CCBW was feasible, safe, and associated with high patient satisfaction among men with advanced CaP receiving diverse systemic therapies. These findings support further evaluation and expansion of decentralized care integrating home-based treatment with virtual clinical oversight.
Real-world outcomes comparing the use of GLP-1 receptor agonists in patients with endometrial cancer and comorbid obesity: A propensity score matched analysis from a global federated health research network.
5543 Background: Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the treatment of type 2 diabetes and obesity. Emerging evidence suggests that these agents may have potential anti-tumor activity as GLP-1 signaling may influence pathways involved in cell proliferation and inflammation. Endometrial cancer is the most common gynecologic malignancy, and obesity represents a well-established, modifiable risk factor that may adversely affect oncologic outcomes through chronic inflammation and metabolic dysregulation. Our study aims to evaluate the impact of GLP-1 receptor agonists on outcomes among patients with endometrial cancer and comorbid obesity. Methods: A retrospective cohort study was conducted using the TriNetX Global Collaborative Network, covering January 2000 to December 2025, encompassing data from 168 global healthcare organizations. Patients aged 18 and above with endometrial cancer and comorbid obesity were identified and then stratified into two groups based on treatment with GLP1 agonists or not. The two groups were then propensity-matched based on age, ethnicity, medical comorbidities, and stage of cancer. Outcomes were assessed for five years from treatment initiation and included overall mortality, myocardial infarction (MI), ischemic stroke; development of peritoneal, lymph node, and visceral metastases; sepsis, pancreatitis, and ED visits. Time-to-event analyses were performed using Kaplan-Meier methods and Cox proportional hazards models. Results: After propensity matching, 6352 patients were included in each cohort with balanced baseline characteristics. Our analysis found that patients with endometrial cancer and comorbid obesity who received GLP-1 agonists had a significantly lower risk of overall mortality (Hazard Ratio [HR]: 0.45, 95% CI: 0.39-0.51, p-value <0.001), development of peritoneal metastases (Risk Difference [RD]: -2.16%, 95% CI: -2.74% to -1.58%, p-value <0.001), nodal metastases (RD: -0.41%, 95% CI: -0.72% to -0.09%, p-value =0.01), visceral metastases (RD: -3.76%, 95% CI: -4.60% to -2.93%, p-value =0.01), and sepsis with and without shock (RD: -1.42%, 95% CI: -2.14% to -0.70%, p-value <0.001) compared to patients who did not receive GLP-1 agonists. There was no statistically significant difference in the rates of MI, ischemic stroke, ED visits, and pancreatitis between the two cohorts. Conclusions: In this large real-world analysis, patients with endometrial cancer and comorbid obesity who received GLP-1 agonists had lower rates of overall mortality; peritoneal, lymph node, and visceral metastases, and sepsis with or without shock. Additional longitudinal cohort studies are imperative to explore the associations between these agents and inform clinical practice guidelines in this patient population.
Abstract C138: Influence of demographic factors and knowledge on prostate cancer screening attitude and research participation among Black men
Abstract Introduction: The disproportionate prostate cancer (CaP) burden, which includes high mortality rates, is significantly attributed to the characteristics of the social determinants of the health status of the Black Male population. Designing targeted interventions to address poor health outcomes through a collaborative population-based approach could reduce CaP health disparities. The Community Living Lab (CoLLab) Learning Health System was developed to address ethnically sensitive, targeted approaches that will eliminate CaP health disparities among Black Men. This study assessed demographic factors and Knowledge on prostate cancer screening attitudes and research participation among black men. Method: The collab project employed a social ecological model to design intervention to address barriers to CaP screening and participation in clinical trials. A validated, pretested questionnaire was used to collect information on demographics, CaP knowledge, attitudes, testing, and a history of participation in research and clinical trials. Baseline data were collected from 3 American Legion posts (ALPs). The association between variables was evaluated using the Chi-square test. Results: Participants between 60-69 years were 28.38%, and those aged 40-49 were 12.16%. Most are US-born Black (89.8%), with others identifying as African-born Black (6.76%) and Caribbean-born Black (1.35%). Approximately 43.24% were retired, and 36.49% were working full-time. CaP knowledge was high in 43.9%, moderate in 46.6%, and low in 9.5%. Only 45% of the participants have undergone Prostate-Specific Antigen test, and 24.6% have had a Digital Rectal Examination. Reported past clinical trials and research participation were very low (9.38%). Participants with higher knowledge levels had higher information scores (p < .0001), favored various research settings (p = 0.0008), had favorable attitudes towards CaP testing (p < .0001), and were more likely to participate in research (p = 0.0117). Work status was found to impact CaP Knowledge (p = 0.0117). Participants with stronger beliefs about prostate cancer may have different attitudes toward testing (p = 0.0444). Age did not impact attitudes toward CaP testing (p = 0.4298). Conclusion: The knowledge of CaP was found to impact the attitudes, testing, and disposition of the participants towards research. The baseline data generated from the clinical study will curate insightful evidence that will create innovative approaches to prostate cancer education among males in Black communities. Citation Format: Opeyemi O. Bolajoko, Quincy A. Wimberly, Daniel W. Lee, Collisa Mahin, Michelle Fudge, Shaina E. Flynn, Arnold J. Merriweather, Trevanne R. Matthews Hew, Monica L. Albertie, Dery Greene, Wayne Ford, Toshiko Moultrie, Floyd B. Willis, Folakemi T. Odedina. Influence of demographic factors and knowledge on prostate cancer screening attitude and research participation among Black men [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr C138.
Abstract C064: Feasibility of an interventional clinical trial addressing prostate cancer disparities in Black men by decentralization (DCT): A potential solution to disparities in clinical trial participation
Abstract Introduction: This ongoing study investigates the impact of vitamin D deficiency on the immune response to prostate cancer (CaP) in Black patients and its potential contribution to CaP disparities. The study also evaluates differences in immune function, including p53 and CaP associated antibody levels, in Black men with localized versus metastatic CaP. Methodology: Eligible patients with a history of localized or metastatic CaP are enrolled following informed consent (in person or remote). At baseline, blood is collected for calcium and vitamin D3 levels, and for immune testing. Patients who participate in the screening portion of the trial and are found to have vitamin D3 levels <30 ng/mL are prescribed oral vitamin D3 (2000 IU daily) and asked to record adherence in a medication diary. Follow-up includes a 4-week check-in and end-of-treatment labs at 8 weeks for calcium, vitamin D3 levels, and immune re-testing. Virtual consults occur after baseline and at 8 weeks. Quality of life is measured at baseline and EOT follow-up using the CDC HRQOL–4. The study began accruing patients in December 2021. In an attempt to accelerate patient accrual, the protocol was amended to become one of Mayo Clinic’s first fully decentralized clinical trials. Newly integrated components included at-home and community-based blood collection (outside of Mayo Clinic southern sites) and continued virtual engagement. These changes were designed to reduce barriers linked to social determinants of health (SDOH) and expand participation among medically underserved populations. This is a report on the impact of clinical trial DCT. Results: From December 2021 to September 2023 (pre-DCT), 24 patients were enrolled from 66 patients who participated in the screening portion for the trial (mean accrual: 1.09/month; SD: 1.15). Following the DCT amendment, enrollment rose to 102 patients from 213 screened (mean: 4.86/month; SD: 3.12) through June 2025. Of 126 enrolled patients, 119 (94.4%) returned medication diaries, with only 6 non-returns occurring post-DCT. QOL measures were completed by approximately 75% of participants. Importantly, 90 of 126 participants (71%) were enrolled from outside Jacksonville, FL or Scottsdale/Phoenix, AZ, indicating successful national expansion. A total of 111 patients failed the screening due to baseline vitamin D levels >30 ng/ml. The total number of protocol deviations increased post-DCT (60 from 10/23–6/25 vs. 14 from 12/21–9/23), there was no change in the number of protocol deviations per enrolled patients. Minor documentation and study timeline deviations were the most common in both periods. Conclusions: The successful implementation of a fully decentralized model was associated with a marked increase in the accrual of underserved patients and allows the completion of critical clinical trials that address important cancer care disparities without impacting protocol integrity. Clinical trial DCT can potentially reduce SDOH-related barriers and improve representation of underserved populations in research. Citation Format: Sandra Casanova Leyva, Kim M. Barbel Johnson, Tufia Haddad, Lydia Mercado, Trevanne Matthews Hew, Cassandra Moore, Gerardo Colon-Otero, Devina Joshi, Roselyn Heduvor. Feasibility of an interventional clinical trial addressing prostate cancer disparities in Black men by decentralization (DCT): A potential solution to disparities in clinical trial participation [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr C064.
A phase I pilot study of personalized neoantigen peptide-based vaccine in combination with pembrolizumab in advanced solid tumors (PNeoVCA).
TPS2700 Background: Though immunotherapy with anti-PD-1 immune checkpoint inhibitors (ICIs) has led to improvements in clinical outcomes in patients with cancer, when used as monotherapy in the advanced setting, only 18-25% of patients respond to ICI. Notably, ICI frequently lacks anti-tumor activity in immune-cold cancers where T cell priming is missing. Recent breakthroughs in identifying personal neoantigens via a comprehensive analysis of cancer sequencing data have brought increased attention to neoantigen cancer vaccines. Personalized cancer vaccines targeting neoantigens have shown early promise. While neoantigens have recently been investigated in some cancer types, the current neoantigen prediction algorithms have often focused on the MHC class-I subtype, single nucleotide mutations (SNM), small insertions and deletions (INDEL). We recently developed an informatics workflow, REAL-neo, for the identification, quality control (QC), and prioritization of both class-I and class-II human leukocyte antigen (HLA) bound neoantigens that arise from somatic SNM, INDEL, aberrant RNA splicing, and gene fusions, generating much more potent neoantigen candidates. Furthermore, we demonstrated robust T-cell response and prolonged survival by combining ICI and cancer vaccines in preclinical models. This single-arm phase I clinical trial is in progress to assess the safety, feasibility, and immunogenicity of personalized neoantigen vaccines in combination with pembrolizumab in patients with advanced solid cancers. Methods: The vaccine consists of up to 20 peptides (15-30 mer) comprising patient-specific neoantigens identified from tumor DNA and mRNA sequencing data using REAL-neo and delivered with GM-CSF as an adjuvant. The first cohort of three patients will be treated at dose level 1 consisting of 4 or 5 peptides at 300 mcg/peptide and GM-CSF 125 mcg per injection site in each of four limbs. After Cohort 1 is deemed safe, the study will expand to cohort 2, when patients will be enrolled at the same dose level for vaccine plus Pembrolizumab 200 mg i.v. Neoantigen vaccine will be given via subcutaneous injection on days 1, 4, 8, 15, and 21 (cohorts 1 and 2) and weeks 5 and 8 (booster dose for cohort 2 only). Cohort 1 has been completed without dose-limiting toxicity (DLT). Enrollment in Cohort 2 began in January 2024. AEs are assessed according to CTCAE v5. and safety findings are reviewed by data safety medical board (DSMB). Key eligibility criteria include 1) histologically confirmed locally advanced or metastatic solid malignancies and 2) cancer progression after at least one line of the standard-of-care (SOC) systemic treatment. For cohort 2, patients must be eligible to receive pembrolizumab per SOC or the treating physician’s judgment. Clinical trial information: NCT05269381 .